source
- J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s VabysmoJohnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
- Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipelineEli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…